I think the point is that her2+status supercedes all the old
oversimplifications as to how ER+ or ER- tumors behave. The subtypes described luminal A (ER+her2-), luminal B (ER+her+ among others), her2 group (ER-her2+) and basal (triple negative) are now considered to be the major groups determining how a tumor behaves and how it responds to treatment.
Just as these old oversimplifications (from 2001) have been superceded, it may turn out that these groups contain subtypes within themselves which will change how breast cancer is thought about and treated in the future eg, there may be subtypes such as ER-her2+uPA+ which have different behavior and respond differently to treatment thatn ER-her2+uPA-.
Stay tuned!
|